INTRODUCTION

Aortic prosthetic graft and cardiac implant infections are infrequent but can have devastating consequences with historically high morbidity and mortality rates. Reported rates of these infections are between 1% and 15%, with an associated mortality rate of 25%–75%.1–3 Furthermore, traditional treatment paradigms are complex, morbid, and associated with unique risks.

The conventional approach to management of vascular graft and cardiac implant infection requires graft explantation with replacement or extra-anatomical bypass. Despite treatment, the reported morbidity and mortality rates are high. The purpose of this study was to present our experience with an innovative approach to aortic graft salvage in the setting of sternal wound infection using antibiotic impregnated polymethylmethacrylate beads followed by definitive wound closure with flap coverage. A retrospective review identified patients with surgical wounds after aortic graft or cardiac valve placement over a 7-year period at a single institution. Patients were treated using an algorithm consisting of repeated surgical debridement and placement of antibiotic beads followed by flap coverage after suppression of the infection. A total of 20 patients were treated for surgical wounds, including 19 sternal and one thoracotomy wound. Culture positive surgical site infections were documented in 16 patients. One patient required a bead exchange before definitive closure. There were no in-hospital mortalities. All but two patients achieved successful infection suppression and wound closure with flap coverage. The use of antibiotic beads with serial debridement and flap closure may offer a valid option for aortic graft salvage in the setting of infected sternal wounds in the appropriate patient population. The proposed algorithm showed that patients may be successfully treated, and their infection suppressed without the need for graft removal. Mortality rates were lower from those previously reported in the literature. (Plast Reconstr Surg Glob Open 2022;10:e4371; doi: 10.1097/GOX.0000000000004371; Published online 10 June 2022.)
METHODS

Institutional review board approval was obtained for a retrospective chart review on all patients treated by the senior author for thoracic wound infections. All patients received a graft or implant during an initial cardiothoracic operation and were treated for an infection between December 2012 and July 2019 at a single institution. Patients received systemic antibiotic therapy, which was tailored to culture results when available. In conjunction with the cardiothoracic team, patients were treated with the same algorithm in an attempt to salvage the graft (Fig. 1).

Patients initially underwent aggressive surgical debridement. If the wound was superficial, sternal wires were left in place, intraoperative cultures were obtained, and antibiotic impregnated polymethylmethacrylate beads were placed above the sternum with temporary complex closure if skin could be approximated without excess tension. If this was not possible, a wound vac was placed. After infection clearance, the beads and wires were removed followed by definitive flap coverage. In these patients, the sternum was allowed to undergo routine bony healing before wire removal. If the mediastinum or aortic graft was involved, the sternal wires were removed during initial debridement, and antibiotic beads were placed on top of an aortic graft with bovine pericardium for graft protection when needed (Fig. 2). Infections were determined to be cleared when there were no signs of infection on intraoperative evaluation, and cultures were negative. Drains were placed in all cases.

Antibiotic beads were created using one package of nonabsorbable polymethylmethacrylate impregnated with 1 g of tobramycin (Simplex P with tobramycin; Stryker, Kalamazoo, Mich.) with an additional 1.2 g of tobramycin (X-GEN Pharmaceuticals, Big Flats, N.Y.) and 2–4 g of vancomycin hydrochloride (Pfizer, New York, N.Y.). All beads were assembled and strung onto a 2-0 Prolene (Ethicon, Inc., Somerville, N.J.) suture, and cured before implantation.

RESULTS

During our 7-year review, 20 patients were treated with antibiotic beads for implant-associated cardiothoracic wound infections by the senior author, according to our surgical algorithm. There were 14 deep infections and six superficial infections. Nineteen patients presented with sternal wound infections, and one with a thoracotomy site infection. (See table, Supplemental Digital Content 1, which shows patient demographics and comorbidities. http://links.lww.com/PRSGO/C52.)

Takeaways

**Question:** Can aortic grafts be salvaged by using antibiotic beads in the setting of sternal wound infections?

**Findings:** Twenty patients with surgical wounds following thoracic aortic graft placement were treated with repeated debridements and placement of antibiotic beads followed by flap coverage after clearance of the infection. Eighteen patients achieved long-term infection suppression, and only one patient required aortic graft replacement.

**Meaning:** The use of antibiotic beads with serial debridement and flap closure offers a valid option for aortic graft salvage in the setting of infected sternal wounds.
The average time from the initial cardiothoracic procedure until infection presentation was 150 days (range 9–939 days), with an average length of initial hospital stay of 20.5 days (Table 1). Cultures taken at the time of debridement and antibiotic bead placement yielded positive results in 16 patients (80%) (Table 1). Twelve patients remained in-house after antibiotic bead placement. Eight were discharged after initial bead placement and returned for elective bead removal and flap coverage. Fasciocutaneous, pectoralis major advancement, pectoralis major turnover, and/or omental flaps were used for sternal wound coverage (Table 1). The average time from infection presentation until flap coverage was 25.2 days (range 8–60 days). No in-hospital mortalities occurred during the initial admission for infection or the subsequent admissions for bead removal and coverage. Eighteen patients with sternal wounds subsequently achieved long-term infection suppression. Two patients developed persistent or recurrent infection, and one patient required thoracic aortic graft replacement.

**DISCUSSION**

Aortic prosthetic graft and cardiac implant infections are devastating complications with challenging management. Coselli et al reported on the use of Dacron tube grafts to treat aortic infections with successful outcomes. Alternatively, cryopreserved aortic homografts have shown better antibiotic diffusion and resistance to recurrent infections; however, graft deterioration is possible. A common theme to these alternatives is the need for multiple subsequent operations and prolonged operative time, with high morbidity.

An alternative method of treatment is the use of antibiotic beads. Polymethylmethacrylate forms a construct with heat-stable antibiotics and allows for the controlled elution directly to the site of infection. Several reports have detailed using antibiotic beads for treating cardiothoracic surgical site infections. Healy et al demonstrated the treatment of a patient with recurrent sepsis, using antibiotics beads following ascending aortic aneurysm repair. Fakhro et al proposed an algorithm with repeated debridement and antibiotic beads to salvage cardiac implantable electronic devices. Additionally, infections of left ventricular assist devices have been treated using antibiotic beads.

In this review, 20 patients with complex cardiothoracic infections were treated via debridement and placement of antibiotic beads followed by definitive wound closure with flap coverage. This treatment algorithm demonstrated successful salvage in patients with sternal wound infections with only one patient requiring graft removal because of infection. The average time from infection presentation until definitive closure was just over 3 weeks. No inpatient mortalities were observed during the initial admission for infection or subsequent admissions for bead removal and closure.

Although the clinical outcomes were impressive, the results were limited by the small sample size at a single institution and the retrospective study design. Additionally, this study lacked a control group and did not compare outcomes of patients receiving antibiotic beads to those receiving traditional treatment regimens.
### Table 1. Infectious and Operative Course

| Patient | Time to Infection (d) | Cultures | Complications | Time to Closure (d) | Final Reconstruction | Reoperation after Flap Coverage | LOS (d) | Readmission | Infection Cleared | Mortality |
|---------|-----------------------|----------|---------------|--------------------|---------------------|-------------------------------|---------|-------------|-------------------|-----------|
| 1       | 9                     | *Klebsiella pneumoniae* | N             | 17                 | Omental flap, b/l fasciocutaneous flaps | N | 26 | N | Y | N |
| 2       | 385                   | *Mycobacterium avium* complex | N             | 18                 | Latissimus dorsi flap | Y | 23 | Y—non-healing wound | N | N |
| 3       | 37                    | MSSA, *Corynebacterium* | Hematoma x3, periaortic collection, graft injury, graft infection | 30                 | R pec turnover flap, L pec adv. flap | Y | 9 | Y—hematoma evacuation, graft infection | N | N |
| 4       | 33                    | Negative | MSSA | 32                 | B/l pec adv. flaps | N | 4 | N | Y | N |
| 5       | 628                   | MRSA     | Pneumonia; graft injury after bead removal | 56                 | B/l pec adv. flaps | N | 67 | N | Y | N |
| 6       | 60                    | CoNS     | N             | 17                 | B/l pec adv. flaps | N | 24 | N | Y | N |
| 7       | 327                   | Negative | *Enterobacter cloacae, Hafnia alvei, CoNS* | 16                 | Split pec turnover flap | N | 9 | N | Y | N |
| 8       | 25                    | Respiratory failure, pleural effusion | N | 11                 | B/l pec adv. flaps | N | 14 | Y—NSTEMI, endocarditis, pericardial effusion, ARF | Y | N |
| 9       | 18                    | *Mycobacterium chelonae* abscessus | N             | 17                 | B/l fasciocutaneous flaps | N | 30 | N | Y | N |
| 10      | 87                    | Negative | N             | 17                 | B/l fasciocutaneous flaps | N | 21 | Y—syncopal episodes | Y | N |
| 11      | 11                    | *Klebsiella pneumonia* | N             | 60                 | B/l pec adv. flaps | N | 7 | N | Y | N |
| 12      | 11                    | *Pseudomonas aeruginosa* | N             | 24                 | B/l pec adv. flaps | N | 23 | Y—afib | Y | N |
| 13      | 959                   | CoNS     | N             | 8                  | R pec turnover flap | N | 13 | N | Y | N |
| 14      | 94                    | MRSA, *pseudomonas* | Pleural effusion | 21                 | B/l pec adv. flaps | N | 28 | N | Y | N |
| 15      | 34                    | MSSA     | Respiratory failure, pleural effusion, pneumonia, afib | 12                 | B/l pec adv. flaps | N | 33 | N | Y | N |
| 16      | 77                    | CoNS     | N             | 27                 | B/l pec adv. flaps | N | 4 | N | Y | N |
| 17      | 52                    | MRSA     | N             | 16                 | B/l pec myocutaneous flaps | N | 22 | N | Y | N |
| 18      | 25                    | Negative | N             | 35                 | B/l pec adv. flaps | N | 11 | N | Y | N |
| 19      | 46                    | CoNS     | N             | 14                 | B/l pec adv. flaps | N | 20 | Y—functional decline | Y | N |

Adv., advancement; afib, atrial fibrillation; b/l, bilateral; CoNS, coagulase-negative *Staphylococcus*; IR, interventional radiology; L, left; LOS, length of stay; MRSA, Methicillin-Resistant *Staphylococcus aureus*; MSSA, Methicillin-Sensitive *Staphylococcus aureus*; N, No; NSTEMI, non-ST-elevation myocardial infarction; pec, pectoralis major muscle; R, right; SOB, shortness of breath; UTI, urinary tract infection; Y, Yes.
CONCLUSIONS

This review adds credibility to the preexisting literature on antibiotic beads and provides a new application for use in thoracic graft associated sternal wound infections. The salvage approach resulted in successful infection suppression and wound closure with limited complications.

Shayan A. Izaddoost, MD, PhD
Department of Plastic Surgery
Kelsey Seybold Clinic
Houston, TX
E-mail: shayanizaddoost@gmail.com

REFERENCES

1. Hodgkiss-Harlow KD, Bandyk DF. Antibiotic therapy of aortic graft infection: treatment and prevention recommendations. Semin Vasc Surg. 2011;24:191–198.
2. Coselli JS, Köksoy C, LeMaire SA. Management of thoracic aortic graft infections. Ann Thorac Surg. 1999;67:1990–1993; discussion 1997.
3. Akowuah E, Narayan P, Angelini G, et al. Management of prosthetic graft infection after surgery of the thoracic aorta: removal of the prosthetic graft is not necessary. J Thorac Cardiovasc Surg. 2007;134:1051–1052.
4. Vogt PR, von Segesser LK, Goffin Y, et al. Cryopreserved arterial homografts for in situ reconstruction of mycotic aneurysms and prosthetic graft infection. Eur J Cardiothorac Surg. 1995;9:502–506.
5. Stone PA, Armstrong PA, Bandyk DF, et al. Use of antibiotic-loaded polymethylmethacrylate beads for the treatment of extravasatory prosthetic vascular graft infections. J Vasc Surg. 2006;44:757–761.
6. LeMaire SA, Coselli JS. Options for managing infected ascending aortic grafts. J Thorac Cardiovasc Surg. 2007;134:839–843.
7. Moehring HD, Gravel C, Chapman MW, et al. Comparison of antibiotic beads and intravenous antibiotics in open fractures. Clin Orthop Relat Res. 2000:254–261.
8. Healy AH, Reid BB, Allred BD, et al. Antibiotic-impregnated beads for the treatment of aortic graft infection. Ann Thorac Surg. 2012;93:984–985.
9. Kretlow JD, Brown RH, Wolfswinkel EM, et al. Salvage of infected left ventricular assist device with antibiotic beads. Plast Reconstr Surg. 2014;133:38e–38e.
10. Fakhro A, Jalalahadi F, Brown RH, et al. Treatment of infected cardiac implantable electronic devices. Semin Plast Surg. 2016;30:60–65.